Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Tue Apr 01 18:31:35 GMT 2025
by
admin
on
Tue Apr 01 18:31:35 GMT 2025
|
| Protein Sub Type | |
| Sequence Type | COMPLETE |
| Record UNII |
D73QL0OMU2
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
P30874
Created by
admin on Tue Apr 01 18:31:35 GMT 2025 , Edited by admin on Tue Apr 01 18:31:35 GMT 2025
|
PRIMARY | |||
|
391971-42-9
Created by
admin on Tue Apr 01 18:31:35 GMT 2025 , Edited by admin on Tue Apr 01 18:31:35 GMT 2025
|
PRIMARY | |||
|
D73QL0OMU2
Created by
admin on Tue Apr 01 18:31:35 GMT 2025 , Edited by admin on Tue Apr 01 18:31:35 GMT 2025
|
PRIMARY |
| From | To |
|---|---|
| 1_115 | 1_193 |
| Glycosylation Type | HUMAN |
| Glycosylation Link Type | Site |
|---|---|
| N | 1_9 |
| N | 1_22 |
| N | 1_29 |
| N | 1_32 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
RADIOLIGAND->TARGET |
|
||
|
RADIOLIGAND->TARGET |
Shows high radioligand uptake in the liver and bone metastases.
IC50
|
||
|
RADIOLIGAND->TARGET |
|
||
|
RADIOLIGAND->TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
|
RADIOLIGAND->TARGET | |||
|
LIGAND->TARGET | |||
|
RADIOLIGAND->TARGET |
Binds with high affinity
|
||
|
|
INHIBITOR -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
BINDING
IC50
|
||
|
|
INHIBITOR -> TARGET | |||
|
LIGAND->TARGET |
|
||
|
LIGAND->TARGET | |||
|
LIGAND->TARGET |
|
||
|
RADIOLIGAND->TARGET |
|
||
|
RADIOLIGAND->TARGET |
ALPHA-PARTICLE EMITTING RADIONUCLIDE
|
||
|
RADIOLIGAND->TARGET |
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
RADIOLIGAND->TARGET |
Lutetium Lu 177 dotatate binds to somatostatin receptors with highest affinity for subtype 2 receptors (SSRT2). Upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor-positive tumors, the compound is internalized. The beta emission from Lu 177 induces cellular damage by formation of free radicals in somatostatin receptor-positive cells and in neighboring cells.
|
||
|
DERIVATIVE -> PARENT |
|
||
|
AGONIST -> TARGET |
IC50
|
||
|
|
RADIOLIGAND->TARGET | |||
|
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET | |||
|
RADIOLIGAND->TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
RADIOLIGAND->TARGET |
|
||
|
|
INHIBITOR -> TARGET | |||
|
LIGAND->TARGET |
|
||
|
RADIOLIGAND->TARGET |
Structural Modifications
| Modification Type | Location Site | Location Type | Residue Modified | Extent | Fragment Name | Fragment Approval |
|---|---|---|---|---|---|---|
| AMINO ACID SUBSTITUTION | [1_353] [1_354] | THREONINE PHOSPHATE | 3L4WX7B1EI | |||
| AMINO ACID SUBSTITUTION | [1_341] [1_343] [1_348] | DEXFOSFOSERINE | VI4F0K069V |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| MOL_WEIGHT | CHEMICAL |
|